Tap MS Research

Aim of the research
There is evidence that the use of medicines in Multiple Sclerosis (MS) may be delayed or impaired because of fears about factors such as drug side effects and/or a lack of belief in their benefits. At the same time, relatively little is published about how best such problems can be addressed and the priorities that People with MS have for future treatment improvements.

The research we are carrying out for Bournemouth University UK is unique because it will explore what patients value most from their treatment and their key expectations for their treatment. The survey we will conduct will provide insight in to the behavioural decisions that delay patients from taking their medication. F. Hoffmann-La Roche Ltd (Roche) have funded this research but they have no part in the design, conduct, analysis or interpretation of the study.

The findings of the survey are available to read in the report below.

Sweden UK Spain Italy Slovakia